The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer
Open accessAbstract
// Jun Li 1, 2 , Jieyu Wang 1, 2 , Ruifang Chen 1, 2 , Yang Bai 1, 2 , Xin Lu 1, 2 1 Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China 2 Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai 200011, China Correspondence to: Xin Lu, email: xinludoc@163.com Keywords: ovarian cancer, tumor-infiltrating lymphocytes, prognosis, survival, meta-analysis Received: September 23, 2016 Accepted: December 20, 2016 Published: January 31, 2017 ABSTRACT The prognostic value of tumor-infiltrating lymphocytes (TILs) in ovarian cancer is still in controversial. This study is aimed to assess the impact of different TIL subsets on the progression free survival (PFS)/disease free survival (DSS) and overall survival (OS)/disease specific survival (DSS) in ovarian cancer. A comprehensive literature search in PubMed, ISI Web of Science, and Medline was performed to identify relevant studies evaluating the prognostic value of TILs in ovarian cancer. Reviews of each study were conducted and data were extracted. The main outcomes analyzed were PFS/DFS and OS/DSS. A total of 21 eligible studies enrolling 2903 ovarian cancer patients were included for the meta-analysis. The overall analysis revealed that intraepithelial CD3 + and CD8 + TILs were strongly associated with improved PFS/DFS (HR=0.53, for CD3 + TILs; and HR=0.50, for CD8 + TILs). Intraepithelial CD8 + /Foxp3 + ratios appeared to be associated with improved PFS, though without reaching statistical significance (HR=0.73). Moreover, intraepithelial CD3 + , CD8 + , and CD103 + TILs were clearly associated with increased OS/DSS (HR=0.50, for CD3 + TILs; HR=0.62, for CD8 + TILs; HR=0.54, for CD103 + TILs). However, intraepithelial FoxP3 + TILs, CD8 + /FoxP3 + ratios, CD8 + /CD4 + ratios, and stromal TILs had no impact on the OS/DSS (HR=0.98, for FoxP3+ TILs; HR=0.69, for CD8 + /FoxP3 + ratios; HR=0.48, for CD8 + /CD4 + ratios; HR=0.82, for stromal TILs). In conclusion, the present meta-analysis supports the hypothesis that intraepithelial TILs are predictive biomarkers for the prognosis of ovarian cancer patients. Future randomized studies are needed to verify these observations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397 · cited 5×
“Increasing evidence indicates that ovarian cancer is an immunogenic disease that can be recognized by the host immune system [3].”
BackgroundMethodInfluentialPlasticity of CD4+ T Cell Lineage Differentiation
Zhou, L., Chong, M. M. W., & Littman, D. R. (2009) · Immunity · doi:10.1016/j.immuni.2009.05.001 · Cited by 1,551 · cited 1×
“The reason is that the expression of FoxP3 by Treg cells may not be stable and that there is a great degree of flexibility in their differentiation options [31].”
BackgroundHamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Cited by
Disis, M. L., Taylor, M. H., Kelly, K., Beck, J. T., Gordon, M., Moore, K. M., Patel, M. R., Chaves, J., Park, H., Mita, A. C., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.6258 · Cited by 437
Watanabe, K., Luo, Y., Da, T., Guedan, S., Ruella, M., Scholler, J., Keith, B., Young, R. M., Engels, B., Sorsa, S., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.99573 · Cited by 283
Schalck, A., Sakellariou-Thompson, D., Forget, M.-A., Sei, E., Hughes, T. G., Reuben, A., Bai, S., Hu, M., Kumar, T., Hurd, M. W., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1248 · Cited by 85
Metadata
- Authors
- Li, J., Wang, J., Chen, R., Bai, Y., & Lu, X.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-01-31
- Volume
- 8
- Issue
- 9
- Pages
- 15621-15631
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2584617802
- Cited by
- 179
- References
- 4
- FWCI
- 20.00
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.